MARKET

HUMA

HUMA

Humacyte Inc
NASDAQ
0.8200
+0.0256
+3.22%
Opening 09:30 03/25 EDT
OPEN
0.8213
PREV CLOSE
0.7944
HIGH
0.8300
LOW
0.8200
VOLUME
191.62K
TURNOVER
--
52 WEEK HIGH
3.360
52 WEEK LOW
0.7010
MARKET CAP
178.76M
P/E (TTM)
-3.7155
1D
5D
1M
3M
1Y
5Y
1D
Wall Street Analysts Think Humacyte, Inc. (HUMA) Is a Good Investment: Is It?
NASDAQ · 2d ago
Humacyte to host fourth-quarter and full-year 2025 financial results webcast and conference call
Reuters · 2d ago
HUMACYTE TO ANNOUNCE 2025 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON MARCH 27, 2026
Reuters · 2d ago
Weekly Report: what happened at HUMA last week (0316-0320)?
Weekly Report · 2d ago
Payroll Figures Due in Canada Next Week
Barchart · 2d ago
A Look At Humacyte (HUMA) Valuation As Symvess Secures Saudi Commitment And Israel Filing
Simply Wall St · 2d ago
Is Humacyte (HUMA) Using Middle East Traction And Equity Issuance To Redefine Its Risk Profile?
Simply Wall St · 4d ago
Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Eledon Pharmaceuticals (ELDN)
TipRanks · 5d ago
More
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

Webull offers Humacyte Inc stock information, including NASDAQ: HUMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HUMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HUMA stock methods without spending real money on the virtual paper trading platform.